XBIO

+ Watchlist + Portfolio

Xenetic Biosciences, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.23
52-Week Range: $1.87 – $13.93
Market Cap: $5.25M
P/E (TTM): —
EPS (TTM): -1.15
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.86
PEG Ratio: —
Return on Equity: -47.04%
Return on Assets: -26.80%
Gross Margin: 100.00%
Operating Margin: -147.09%
Profit Margin: -75.91%
Current Ratio: 7.43
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-1.17M
Revenue Growth: 12.00%
Earnings Growth: —
Enterprise Value: $-1.22M

XBIO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.71M	$2.54M	$2.50M	$2.98M
Research & Development	$4.77M	$3.49M	$3.29M	$3.07M
Selling, General & Admin	$3.65M	$3.56M	$3.42M	$2.75M
Operating Expenses	$8.42M	$7.06M	$6.70M	$5.81M
Operating Income	-$6.72M	-$4.52M	-$4.20M	-$2.83M
EBITDA	-$6.69M	-$4.52M	-$4.20M	-$2.83M
Pretax Income	-$6.55M	-$4.13M	-$3.96M	-$2.68M
Net Income	-$6.55M	-$4.13M	-$3.96M	-$2.68M
Diluted EPS	-4.61	-2.71	-2.57	-1.58
Diluted Shares	1.42M	1.53M	1.54M	1.70M

XBIO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.10M	$8.98M	$6.17M	$7.88M
Current Assets	$13.65M	$9.59M	$6.59M	$8.05M
Total Assets	$14.72M	$10.61M	$6.90M	$8.36M
Current Liabilities	$1.07M	$809.59K	$894.26K	$968.02K
Total Liabilities	$1.07M	$809.59K	$894.26K	$968.02K
Retained Earnings	-$189.10M	-$193.23M	-$197.19M	-$199.88M
Shareholders' Equity	$13.65M	$9.80M	$6.01M	$7.40M
Working Capital	$12.58M	$8.78M	$5.69M	$7.08M

XBIO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.65M	-$4.11M	-$2.82M	-$2.29M
Capital Expenditure	-$500.00K	—	—	—
Free Cash Flow	-$5.15M	-$4.11M	-$2.82M	-$2.29M
Depreciation & Amortisation	$27.04K	$0.00	—	—
Stock-Based Compensation	$511.48K	$283.08K	$171.81K	$64.79K
Investing Cash Flow	-$500.00K	$0.00	—	—
Financing Cash Flow	$0.00	—	$0.00	$4.00M
Net Change in Cash	-$5.15M	-$4.11M	-$2.82M	$1.72M

XBIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$593.26K	$589.90K	$1.03M	$766.30K	$806.92K	$660.60K
Research & Development	$879.03K	$656.56K	$756.48K	$773.42K	$661.44K	$552.01K
Selling, General & Admin	$656.64K	$657.75K	$815.21K	$615.91K	$647.60K	$1.08M
Operating Expenses	$1.54M	$1.31M	$1.57M	$1.39M	$1.31M	$1.63M
Operating Income	-$942.41K	-$724.41K	-$544.73K	-$623.03K	-$502.12K	-$971.69K
EBITDA	-$942.41K	-$724.41K	-$544.73K	-$623.03K	-$502.12K	-$971.69K
Pretax Income	-$903.14K	-$688.70K	-$509.94K	-$579.08K	-$456.38K	-$929.70K
Net Income	-$903.14K	-$688.70K	-$509.94K	-$579.08K	-$456.38K	-$929.70K
Diluted EPS	-0.59	-0.45	-0.33	—	-0.20	-0.41
Diluted Shares	1.54M	1.54M	1.54M	—	2.29M	2.29M

XBIO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.16M	$4.78M	$4.12M	$7.88M	$7.35M	$6.47M
Current Assets	$5.48M	$5.35M	$5.07M	$8.05M	$7.60M	$6.65M
Total Assets	$5.79M	$5.35M	$5.07M	$8.36M	$7.91M	$6.97M
Current Liabilities	$667.93K	$903.43K	$1.11M	$968.02K	$958.24K	$894.98K
Total Liabilities	$667.93K	$903.43K	$1.11M	$968.02K	$958.24K	$894.98K
Retained Earnings	-$198.10M	-$198.79M	-$199.30M	-$199.88M	-$200.33M	-$201.26M
Shareholders' Equity	$5.12M	$4.45M	$3.96M	$7.40M	$6.95M	$6.07M
Working Capital	$4.81M	$4.45M	$3.96M	$7.08M	$6.64M	$5.76M

XBIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.00M	-$383.83K	-$658.25K	-$242.68K	-$536.38K	-$875.49K
Free Cash Flow	-$1.00M	-$383.83K	-$658.25K	-$242.68K	-$536.38K	-$875.49K
Stock-Based Compensation	$19.25K	$15.68K	$15.86K	$14.00K	$11.31K	$51.96K
Net Change in Cash	-$1.00M	-$383.83K	-$658.25K	$3.76M	-$536.38K	-$875.49K

Market Snapshot

About

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immunotherapies for cancer and other life-threatening diseases. The company's pipeline includes XCART, a personalized CAR T cell platform technology, and other oncology-focused programs. Xenetic is developing novel approaches to harness the immune system to fight cancer and improve patient outcomes.